Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$57.86 USD
+3.67 (6.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $57.82 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
KROS 57.86 +3.67(6.77%)
Will KROS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KROS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KROS
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
KROS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for KROS
Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call
Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012
Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)
Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS)
Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment